氯雷他定市场 - 按剂型（片剂、胶囊、糖浆）、给药途径（口服、外用）、类型（品牌、仿製药）、配销通路（医院药房、零售药房、线上药局）、全球预测（ 2024 - 2032）

在药物配方进步和消费者意识提高的推动下，2024年至2032年全球氯雷他定市场将以2.8%的复合年增长率成长。药物输送和增强配方方面的创新正在提高氯雷他定的疗效和患者依从性，使其成为缓解过敏的首选。此外，越来越多的消费者对过敏管理和非困倦抗组织胺的好处的教育正在推动产品需求。这些因素，加上有效的营销策略，以及氯雷他定在不断发展的製药领域中日益增长的重要性，将有利于行业的成长。

氯雷他定市场分为剂型、给药途径、类型、配销通路和地区。

从剂型来看，由于消费者对服用便利性和剂量准确性的偏好不断提高，胶囊领域的行业规模将在 2024 年至 2032 年间大幅增长。胶囊提供方便的包装和有效的抗组织胺递送，同时满足寻求缓解过敏的广大用户的需求。吸引医疗保健提供者和消费者的便携性和货架稳定性等属性也将刺激产品需求。

根据配销通路，到 2032 年，医院药房领域的氯雷他定行业将获得可观的收益，这得益于其在过敏等急性和慢性疾病药物配药方面的强大作用。庞大的患者群体和治疗方案中抗组织胺的广泛使用导致医院对产品的高需求。随着全球医疗保健设施和患者入院人数的增加，医院药房对于推动大部分氯雷他定销售同时确保广泛的可及性和分销变得至关重要。

由于过敏和呼吸道疾病发生率的增加，2024年至2032年亚太地区氯雷他定产业份额将以显着的复合年增长率扩大。快速的城市化、不断增加的医疗保健支出以及不断扩大的医疗保健服务范围导致了更高的产品需求。此外，监管部门的批准和不断增长的药品投资正在推动该地区的市场成长。

目录

第 1 章：方法与范围

第 2 章：执行摘要

第 3 章：产业洞察

• 产业生态系统分析
• 产业影响力
  • 成长动力
    • 过敏性疾病的盛行率不断增加
    • 非处方 (OTC) 配方的可用性
    • 增加氯雷他定组合的研发
  • 产业陷阱与挑战
    • 潜在副作用的风险
    • 与其他抗组织胺的竞争
• 成长潜力分析
• 监管环境
• 波特的分析
• PESTEL分析

第 4 章：竞争格局

• 介绍
• 公司矩阵分析
• 主要市场参与者的竞争分析
• 竞争定位矩阵
• 战略仪表板

第 5 章：市场估计与预测：按剂型，2021 - 2032 年

• 主要趋势
• 平板电脑
• 胶囊
• 糖浆
• 其他剂型

第 6 章：市场估计与预测：按管理途径，2021 年至 2032 年

• 主要趋势
• 口服
• 专题

第 7 章：市场估计与预测：按类型，2021 - 2032

• 主要趋势
• 品牌化
• 泛型

第 8 章：市场估计与预测：按配销通路划分，2021 - 2032 年

• 主要趋势
• 医院药房
• 零售药房
• 网路药房

第 9 章：市场估计与预测：按地区，2021 - 2032

• 主要趋势
• 北美洲
  • 我们
  • 加拿大
• 欧洲
  • 德国
  • 英国
  • 法国
  • 西班牙
  • 义大利
  • 荷兰
  • 欧洲其他地区
• 亚太地区
  • 中国
  • 日本
  • 印度
  • 澳洲
  • 韩国
  • 亚太地区其他地区
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 拉丁美洲其他地区
• 中东和非洲
  • 南非
  • 沙乌地阿拉伯
  • 阿联酋
  • 中东和非洲其他地区

第 10 章：公司简介

• Bayer AG
• Cadila Pharmaceuticals Limited
• Cipla Ltd.
• Lannett Company, Inc.
• Merck KGaA
• Morepen Laboratories Ltd
• Perrigo Company plc
• Pfizer Inc.
• Sun Pharmaceutical Industries Limited
• Viatris Inc.

Global Loratadine Market will grow at 2.8% CAGR from 2024 to 2032, propelled by advancements in pharmaceutical formulations and increased consumer awareness. Innovations in drug delivery and enhanced formulations are improving the efficacy and patient compliance of loratadine, making it a preferred choice for allergy relief. Also, the growing consumer education about allergy management and the benefits of non-drowsy antihistamines are boosting the product demand. These factors, coupled with effective marketing strategies, and the growing importance of loratadine in the evolving pharmaceutical landscape will favor the industry growth.

The loratadine market is fragmented into dosage form, route of administration, type, distribution channel, and region.

By dosage form, the industry size from the capsules segment will experience a substantial surge between 2024 and 2032, fueled by rising consumer preference for ease of ingestion and dosage accuracy. Capsules offer convenient packaging and effective delivery of antihistamine while catering to a broad spectrum of users seeking allergy relief. Attributes like portability and shelf stability to appeal to both healthcare providers and consumers will also boost the product demand.

Based on distribution channel, the loratadine industry from the hospital pharmacy segment will capture sizable gains through 2032, driven by strong role in dispensing medications for acute and chronic conditions like allergies. The large patient base and extensive use of antihistamines in treatment protocols is contributing to high product demand in hospitals. With increasing healthcare facilities and patient admissions globally, hospital pharmacies have grown crucial for driving the majority of loratadine sales while ensuring widespread accessibility and distribution.

Asia Pacific loratadine industry share will expand at a noteworthy CAGR from 2024 to 2032, owing to increasing incidences of allergies and respiratory conditions. Rapid urbanization, rising healthcare expenditure, and expanding access to healthcare services are contributing to higher product demand. Moreover, regulatory approvals and growing investments in pharmaceuticals are bolstering the market growth in the region.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market scope & definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates & calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increasing prevalence of allergic conditions
    • 3.2.1.2 Availability of over-the-counter (OTC) formulations
    • 3.2.1.3 Increasing R&D in loratadine combinations
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 Risk of potential side-effects
    • 3.2.2.2 Competition from other antihistamines
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Porter's analysis
• 3.6 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company matrix analysis
• 4.3 Competitive analysis of major market players
• 4.4 Competitive positioning matrix
• 4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Dosage Form, 2021 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Tablets
• 5.3 Capsules
• 5.4 Syrups
• 5.5 Other dosage forms

Chapter 6 Market Estimates and Forecast, By Route of Administration, 2021 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 Oral
• 6.3 Topical

Chapter 7 Market Estimates and Forecast, By Type, 2021 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 Branded
• 7.3 Generics

Chapter 8 Market Estimates and Forecast, By Distribution Channel, 2021 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 Hospital pharmacy
• 8.3 Retail pharmacy
• 8.4 Online pharmacy

Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

• 9.1 Key trends
• 9.2 North America
  • 9.2.1 U.S.
  • 9.2.2 Canada
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 France
  • 9.3.4 Spain
  • 9.3.5 Italy
  • 9.3.6 Netherlands
  • 9.3.7 Rest of Europe
• 9.4 Asia Pacific
  • 9.4.1 China
  • 9.4.2 Japan
  • 9.4.3 India
  • 9.4.4 Australia
  • 9.4.5 South Korea
  • 9.4.6 Rest of Asia Pacific
• 9.5 Latin America
  • 9.5.1 Brazil
  • 9.5.2 Mexico
  • 9.5.3 Rest of Latin America
• 9.6 Middle East and Africa
  • 9.6.1 South Africa
  • 9.6.2 Saudi Arabia
  • 9.6.3 UAE
  • 9.6.4 Rest of Middle East and Africa

Chapter 10 Company Profiles

• 10.1 Bayer AG
• 10.2 Cadila Pharmaceuticals Limited
• 10.3 Cipla Ltd.
• 10.4 Lannett Company, Inc.
• 10.5 Merck KGaA
• 10.6 Morepen Laboratories Ltd
• 10.7 Perrigo Company plc
• 10.8 Pfizer Inc.
• 10.9 Sun Pharmaceutical Industries Limited
• 10.10 Viatris Inc.